Paul R Waldron, MD
Infectious Disease · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Hospitals listed: Kaiser Foundation Hospital-San Jose. That is not proof they admit you there this week.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Waldron’s office at (408) 972-3000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A120662 · Current
Licensed to practise in California · since 2012 · expires 2027-08-31 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Kaiser Foundation Hospital-San JoseSan Jose, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Kaiser Permanente, which runs 41 hospitals in 3 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.258, Oct 2024 – Sep 2025
See every measure and the patient survey for Kaiser Foundation Hospital-San Jose
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 2 the same, 0 worse of 2 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.258 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.22 to 2.37) · 181 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.43 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 271 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 2,952 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.04 to 0.5) · 894 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 908 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.19 (0.67 to 5.72) · 176 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 61 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.23 (0.53 to 3.92) · 168 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.11 (0 to 17.58) · 68 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.85 (0.67 to 9.03) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.43 (0 to 1.53) · 630 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 48 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.843 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.88 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.611 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 171 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 571 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 147.1 · 28 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 21 · 639 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 48 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 157 cases | None | Jul 2023 – Jun 2025 |
What patients said (1,294 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 61% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$3,437
Medicare paid this office $3,437 for 23 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
23 Original Medicare patients in 2024. Average age 65 · Under 65 52% · Health risk score 4.97. Sicker patients than 9 in 10 peers; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Diabetes 74% · Chronic kidney disease 57% · Heart failure 48%.
The office billed $7,746, Medicare allowed $4,535 and paid $3,437; for 43 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 23 | 43 | 65 | 4.97 | $7,746 | $3,437 |
| 2023 | 23 | 52 | 68 | 4.52 | $7,665 | $4,080 |
| 2022 | 14 | 63 | 66 | 3.35 | $6,858 | $3,428 |
| 2021 | 14 | 45 | 63 | 2.31 | $5,576 | $3,032 |
| 2020 | 11 | 25 | 71 | 2.23 | $3,116 | $1,318 |
| 2019 | 13 | 21 | 64 | 4.62 | $3,931 | $1,296 |
| 2018 | 21 | 39 | 64 | 3.91 | $7,569 | $2,297 |
| 2017 | 17 | 25 | 68 | 1.73 | $4,993 | $1,571 |
| 2016 | 48 | 91 | 72 | 4.14 | $28,319 | $7,830 |
| 2015 | 84 | 252 | 71 | 3.02 | $81,551 | $22,616 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,212 | $71 |
2017: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $927 | $58 |
2016: 1 service
| Long return visit (40+ min) | 11 | $1,109 | $92 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $6,998 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,832 | $179 |
| Hospital discharge day management, 30 minutes or less | 38 | $2,592 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,493 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,468 | $122 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $768 | $35 |
Drugs they prescribed that Part D paid
$1,542,484
Pharmacies billed $1,542,484 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,070) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
845 generic and fewer than 11 brand-name prescriptions · $1,542,484 in drug cost · 410 antibiotic prescriptions to 133 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 69 | $540,675 | $7,836 |
| Nuzyra | 14 | $218,365 | $15,598 |
| Odefsey | 15 | $117,549 | $7,837 |
| Thalomid | 11 | $83,567 | $7,597 |
| Amoxicillin | 52 | $3,267 | $63 |
See all 29 drugs
| Biktarvy | 69 | $540,675 | $7,836 |
| Nuzyra | 14 | $218,365 | $15,598 |
| Odefsey | 15 | $117,549 | $7,837 |
| Thalomid | 11 | $83,567 | $7,597 |
| Amoxicillin | 52 | $3,267 | $63 |
| Vancomycin | 12 | $2,902 | $242 |
| Rifampin | 24 | $2,865 | $119 |
| Doxycycline Monohydrate | 70 | $2,723 | $39 |
| Voriconazole | 22 | $2,158 | $98 |
| Cephalexin | 45 | $2,140 | $48 |
| Linezolid | 43 | $2,111 | $49 |
| Menveo A-C-Y-W-135-Dip | 12 | $1,812 | $151 |
| Cefpodoxime Proxetil | 14 | $1,658 | $118 |
| Ethambutol | 12 | $1,395 | $116 |
| Amoxicillin-Clavulanate Potass | 30 | $1,372 | $46 |
| Fluconazole | 29 | $1,203 | $41 |
| Ciprofloxacin | 34 | $689 | $20 |
| Azithromycin | 24 | $656 | $27 |
| Levofloxacin | 21 | $266 | $13 |
| Lisinopril-Hydrochlorothiazide | 21 | $253 | $12 |
| Atorvastatin | 25 | $242 | $10 |
| Amlodipine Besylate | 20 | $218 | $11 |
| Levothyroxine | 13 | $211 | $16 |
| Tamsulosin | 11 | $165 | $15 |
| Famotidine | 13 | $141 | $11 |
| Metoprolol | 13 | $135 | $10 |
| Sulfamethoxazole-Trimethoprim | 12 | $108 | $9 |
| Furosemide | 12 | $105 | $9 |
| Meloxicam | 13 | $80 | $6 |
Year by year
| 2024 | 1,070 | 191 | 0% (0) | None | $1,542,484 |
| 2023 | 864 | 152 | None | None | $1,150,780 |
| 2022 | 697 | 109 | None | None | $794,471 |
| 2021 | 630 | 96 | None | 28% | $827,418 |
| 2020 | 552 | 87 | 0% (0) | 28% | $745,909 |
| 2019 | 592 | 101 | None | 32% | $946,520 |
| 2018 | 730 | 127 | 0% (0) | 39% | $769,531 |
| 2017 | 650 | 103 | None | 39% | $529,737 |
| 2016 | 218 | 57 | None | 26% | $107,806 |
| 2015 | 165 | 39 | None | None | $96,598 |
| 2014 | 29 | None | None | None | $9,402 |
| 2013 | 110 | 28 | None | 15% | $15,430 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Biktarvy | 54 | $415,845 | $7,701 |
| Thalomid | 12 | $101,802 | $8,483 |
| Odefsey | 17 | $80,249 | $4,721 |
| Tivicay | 14 | $28,264 | $2,019 |
| Rifampin | 21 | $2,764 | $132 |
| Amoxicillin | 40 | $1,976 | $49 |
| Ethambutol | 19 | $1,788 | $94 |
| Lamivudine | 13 | $1,726 | $133 |
| Amoxicillin-Clavulanate Potass | 30 | $1,147 | $38 |
| Doxycycline Monohydrate | 28 | $1,099 | $39 |
| Cephalexin | 24 | $954 | $40 |
| Linezolid | 11 | $825 | $75 |
| Fluconazole | 34 | $786 | $23 |
| Azithromycin | 18 | $577 | $32 |
| Ciprofloxacin | 35 | $508 | $15 |
| Atorvastatin | 37 | $364 | $10 |
| Levofloxacin | 15 | $335 | $22 |
| Lisinopril-Hydrochlorothiazide | 25 | $244 | $10 |
| Levothyroxine | 13 | $240 | $18 |
| Lisinopril | 11 | $128 | $12 |
| Hydrochlorothiazide | 11 | $125 | $11 |
| Famotidine | 11 | $118 | $11 |
| Amlodipine Besylate | 19 | $112 | $6 |
2022: 19 drugs
| Biktarvy | 39 | $296,892 | $7,613 |
| Odefsey | 19 | $69,877 | $3,678 |
| Tivicay | 19 | $45,138 | $2,376 |
| Rifampin | 35 | $4,762 | $136 |
| Ethambutol | 23 | $2,093 | $91 |
| Fluconazole | 17 | $1,742 | $102 |
| Azithromycin | 27 | $1,094 | $41 |
| Doxycycline Monohydrate | 19 | $898 | $47 |
| Amoxicillin | 19 | $812 | $43 |
| Amoxicillin-Clavulanate Potass | 16 | $549 | $34 |
| Cephalexin | 14 | $508 | $36 |
| Levothyroxine | 17 | $385 | $23 |
| Levofloxacin | 15 | $295 | $20 |
| Atorvastatin | 28 | $258 | $9 |
| Famotidine | 17 | $217 | $13 |
| Lisinopril | 14 | $163 | $12 |
| Lisinopril-Hydrochlorothiazide | 20 | $163 | $8 |
| Hydrochlorothiazide | 13 | $149 | $11 |
| Amlodipine Besylate | 21 | $127 | $6 |
2021: 17 drugs
| Biktarvy | 26 | $206,270 | $7,933 |
| Triumeq | 13 | $101,289 | $7,791 |
| Odefsey | 22 | $64,712 | $2,941 |
| Tivicay | 23 | $48,467 | $2,107 |
| Intelence | 11 | $35,513 | $3,228 |
| Rifampin | 25 | $8,508 | $340 |
| Fluconazole | 24 | $2,440 | $102 |
| Voriconazole | 11 | $1,850 | $168 |
| Ethambutol | 15 | $1,202 | $80 |
| Amoxicillin | 25 | $982 | $39 |
| Azithromycin | 14 | $889 | $63 |
| Cephalexin | 19 | $847 | $45 |
| Doxycycline Monohydrate | 20 | $739 | $37 |
| Amoxicillin-Clavulanate Potass | 14 | $531 | $38 |
| Atorvastatin | 32 | $299 | $9 |
| Ciprofloxacin | 12 | $255 | $21 |
| Amlodipine Besylate | 14 | $92 | $7 |
2020: 17 drugs
| Biktarvy | 20 | $163,267 | $8,163 |
| Tivicay | 19 | $50,447 | $2,655 |
| Intelence | 11 | $46,946 | $4,268 |
| Prezcobix | 12 | $45,985 | $3,832 |
| Descovy | 11 | $35,001 | $3,182 |
| Odefsey | 11 | $30,590 | $2,781 |
| Rifampin | 19 | $4,923 | $259 |
| Fluconazole | 16 | $1,986 | $124 |
| Cephalexin | 33 | $1,517 | $46 |
| Amoxicillin | 35 | $1,378 | $39 |
| Ethambutol | 14 | $1,154 | $82 |
| Lactulose | 16 | $605 | $38 |
| Azithromycin | 15 | $570 | $38 |
| Ciprofloxacin | 14 | $382 | $27 |
| Mupirocin | 12 | $249 | $21 |
| Atorvastatin | 21 | $239 | $11 |
| Chlorhexidine Gluconate | 13 | $158 | $12 |
2019: 17 drugs
| Triumeq | 15 | $126,236 | $8,416 |
| Biktarvy | 13 | $98,976 | $7,614 |
| Odefsey | 12 | $93,244 | $7,770 |
| Descovy | 15 | $65,709 | $4,381 |
| Dificid | 12 | $58,286 | $4,857 |
| Intelence | 13 | $57,321 | $4,409 |
| Prezcobix | 11 | $52,814 | $4,801 |
| Prezista | 11 | $46,494 | $4,227 |
| Xifaxan | 11 | $24,563 | $2,233 |
| Rifampin | 27 | $4,902 | $182 |
| Fluconazole | 20 | $3,000 | $150 |
| Voriconazole | 11 | $1,553 | $141 |
| Doxycycline Monohydrate | 24 | $1,220 | $51 |
| Lactulose | 32 | $809 | $25 |
| Amoxicillin | 18 | $705 | $39 |
| Cephalexin | 19 | $417 | $22 |
| Atorvastatin | 15 | $324 | $22 |
2018: 24 drugs
| Triumeq | 23 | $148,064 | $6,438 |
| Odefsey | 19 | $102,497 | $5,395 |
| Descovy | 19 | $72,313 | $3,806 |
| Tivicay | 22 | $64,788 | $2,945 |
| Genvoya | 14 | $48,871 | $3,491 |
| Prezista | 15 | $40,143 | $2,676 |
| Xifaxan | 17 | $35,968 | $2,116 |
| Voriconazole | 14 | $7,861 | $562 |
| Fluconazole | 33 | $4,953 | $150 |
| Vancomycin | 14 | $4,903 | $350 |
| Ritonavir | 16 | $2,394 | $150 |
| Omega-3 Acid Ethyl Esters | 11 | $1,597 | $145 |
| Dapsone | 14 | $1,422 | $102 |
| Rifampin | 19 | $1,370 | $72 |
| Lactulose | 33 | $905 | $27 |
| Amoxicillin | 30 | $791 | $26 |
| Doxycycline Monohydrate | 17 | $689 | $41 |
| Cephalexin | 21 | $686 | $33 |
| Azithromycin | 18 | $579 | $32 |
| Amoxicillin-Clavulanate Potass | 13 | $501 | $39 |
| Atorvastatin | 18 | $390 | $22 |
| Ciprofloxacin | 13 | $370 | $28 |
| Lisinopril | 15 | $218 | $15 |
| Sulfamethoxazole-Trimethoprim | 13 | $147 | $11 |
2017: 21 drugs
| Odefsey | 14 | $78,313 | $5,594 |
| Triumeq | 17 | $77,485 | $4,558 |
| Tivicay | 23 | $67,691 | $2,943 |
| Descovy | 19 | $52,354 | $2,755 |
| Genvoya | 12 | $30,310 | $2,526 |
| Prezista | 13 | $28,590 | $2,199 |
| Voriconazole | 11 | $5,868 | $533 |
| Norvir | 16 | $4,757 | $297 |
| Fluconazole | 26 | $4,331 | $167 |
| Rifampin | 27 | $1,873 | $69 |
| Menveo A-C-Y-W-135-Dip | 13 | $1,534 | $118 |
| Dapsone | 13 | $1,375 | $106 |
| Ciprofloxacin | 24 | $1,119 | $47 |
| Amoxicillin | 33 | $963 | $29 |
| Lactulose | 20 | $660 | $33 |
| Cephalexin | 14 | $488 | $35 |
| Azithromycin | 24 | $429 | $18 |
| Atorvastatin | 18 | $350 | $19 |
| Levofloxacin | 17 | $245 | $14 |
| Sulfamethoxazole-Trimethoprim | 16 | $205 | $13 |
| Doxycycline Monohydrate | 11 | $201 | $18 |
2016: 1 drug
| Atorvastatin | 13 | $115 | $9 |
2015: 3 drugs
| Complera | 12 | $26,464 | $2,205 |
| Atripla | 12 | $25,259 | $2,105 |
| Atorvastatin | 15 | $89 | $6 |
2013: 1 drug
| Simvastatin | 13 | $104 | $8 |
Professional record
- NPI
- 1962674283
- Licence
- CA A120662California A120662: Current · expires 2027-08-31
- Trained
- Johns Hopkins University School of Medicine, 2009
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-03-26
- NPI last updated
- 2015-07-28
This is when the NPI record was last certified, not a medical board exam.